GlassScriptPhysician profile
Jacqueline Flaherty
NPI 1316622640
$3,585.25
in general payments reported to CMS, 2019-2025
15 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $249 · 2024: $2,314 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,404 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.85 |
| Education | $181.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,088.40 | 2023-2025 | |
| Ucb, INC. | $783.36 | 2023-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $527.05 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $297.91 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $238.05 | 2024-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $132.06 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Galderma Laboratories, L.P. | $114.32 | 2024 | Aklief |
| Amgen INC. | $87.41 | 2024 | Otezla |
| Genzyme Corporation | $86.11 | 2024-2025 | |
| Organon LLC | $58.57 | 2024-2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $53.01 | 2024 | |
| Sun Pharmaceutical Industries INC. | $43.48 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.73 | 2024 | Arazlo |
| Pfizer INC. | $21.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.